Arlene O. Siefker-Radtke, MD:Most recently, we have opened the PIVOT-10 trial, which is a clinical trial of bempegaldesleukin plus nivolumab in patients with stage IV metastatic surgically unresectable urothelial cancer who are not candidates for cisplatin-based chemotherapy and have low PD-L1 [programmed death-ligand 1] expression. This clinical trial has an arm combining bempegaldesleukin with nivolumab given on a 3-week schedule. There’s a reference arm studying gemcitabine-carboplatin in this group of patients as well. So patients will be randomized to either bempegaldesleukin plus nivolumab or gemcitabine-carboplatin.
The gemcitabine-carboplatin arm is not going to be compared directly against the response rate, but rather it’s to provide a reference as to what the objective response rate would be with carboplatin-based chemotherapy and PD-L1low tumors. One reason for this strategy is that there have been thoughts raised that perhaps chemotherapy doesn’t work as well in PD-L1–low tumors. If we look in the neoadjuvant setting, there are data suggesting cisplatin-based chemotherapy has the highest impact in a basal subtype of bladder cancer, and that basal subtype typically has the highest levels of PD-L1 expression.
So this trial design will provide a referent arm on the response rate associated with gemcitabine-carboplatin.
Patients randomized to gemcitabine-carboplatin will be allowed to receive treatment with bempegaldesleukin plus nivolumab upon progression from gemcitabine-carboplatin, which will also provide some intriguing information on the use of this combination in a postchemotherapy setting.
Transcript edited for clarity.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
Study Shows Desire for Bladder-Sparing Treatments in High-Risk NMIBC
April 2nd 2024In an interview with Targeted Oncology, Joseph M. Jacob, MD, discussed how bladder preservation is the top reason for refusal of radical cystectomy in the TAR-200 monotherapy cohort of the SunRISe-1 study.
Read More